Development asset linked to Advanced Accelerator Applications in public FDA and regional records.
pharma · Allergies · Early Parkinson Disease
Advanced Accelerator Applications
Advanced Accelerator Applications drug portfolio — 25 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
20 rue Diesel, Saint Genis Pouilly, 01630, FR, RUEIL-MALMAISON HQ
590 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- 20 rue Diesel, Saint Genis Pouilly, 01630, FR, RUEIL-MALMAISON
- Employees
- 590
- Programs
- 12
- Drugs
- 25
- Patents
- 25
Advanced Accelerator Applications pipeline
Portfolio lens on 25 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Advanced Accelerator Applications drug portfolio — 25 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
arginine
Various (V03)Various (V03) compound in Advanced Accelerator Applications's portfolio.
-
Development asset linked to Advanced Accelerator Applications in public FDA and regional records.
-
Development asset linked to Advanced Accelerator Applications in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to Advanced Accelerator Applications in public FDA and regional records.
-
Development asset linked to Advanced Accelerator Applications in public FDA and regional records.
-
Development asset linked to Advanced Accelerator Applications in public FDA and regional records.
-
Development asset linked to Advanced Accelerator Applications in public FDA and regional records.
-
Development asset linked to Advanced Accelerator Applications in public FDA and regional records.
-
Development asset linked to Advanced Accelerator Applications in public FDA and regional records.
-
Development asset linked to Advanced Accelerator Applications in public FDA and regional records.
-
lutetium (177lu) oxodotreotide
Various (V10)Various (V10) compound in Advanced Accelerator Applications's portfolio. Molecular target: Somatostatin receptor.
- Target
- Somatostatin receptor
- Mechanism
- Somatostatin receptor binding agent
-
US regulatory status: approved. Molecular target: Progesterone receptor.
- Target
- Progesterone receptor
- Mechanism
- Progesterone receptor agonist
-
Development asset linked to Advanced Accelerator Applications in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Somatostatin receptor.
- Target
- Somatostatin receptor
- Mechanism
- Somatostatin receptor agonist
-
Development asset linked to Advanced Accelerator Applications in public FDA and regional records.
-
Development asset linked to Advanced Accelerator Applications in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
Development asset linked to Advanced Accelerator Applications in public FDA and regional records.
-
Development asset linked to Advanced Accelerator Applications in public FDA and regional records.
-
Development asset linked to Advanced Accelerator Applications in public FDA and regional records.
-
Development asset linked to Advanced Accelerator Applications in public FDA and regional records.
-
Development asset linked to Advanced Accelerator Applications in public FDA and regional records.
-
Development asset linked to Advanced Accelerator Applications in public FDA and regional records.